10Q--pre view of RA P3 progress: third party expenditures on Diagnostics development down 8% ytd f | NAVB Message Board Posts


Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  37772 of 38282  at  8/15/2022 5:28:18 PM  by

moneyonomics


 In response to msg 37770 by  FIRAC
view thread

Re: 10Q--pre view of RA P3 progress: third party expenditures on Diagnostics development down 8% ytd from 2021..therapeutics flat

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...